X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Phase 1/2 clinical trial will evaluate CM24, a monoclonal antibody targeting CEACAM1, in combination with nivolumab (Opdivo®) in patients with advanced non-small cell lung cancer.
Lead Product(s): CM-24,Nivolumab,Paclitaxel
Therapeutic Area: Oncology Product Name: CM-24
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer.
Lead Product(s): NT219,Cetuximab
Therapeutic Area: Oncology Product Name: NT219
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Kitov is currently advancing preparations to initiate a Phase 1/2 clinical trial of CM24 in combination with Opdivo in patients with non-small cell lung cancer, and in combination with nivolumab in addition to standard of care chemotherapy in patients with pancreatic cancer.
Lead Product(s): CM-24,Nivolumab
Therapeutic Area: Oncology Product Name: CM-24
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
The primary objectives of the open-label Phase 1/2 trial are to evaluate safety, assess pharmacokinetics, identify the appropriate dose to be studied in the Phase 2 portion, and establish preliminary efficacy of NT219.
Lead Product(s): NT219
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2020
Details:
Positive results of a previously reported Phase 1 trial of CM-24, a monoclonal antibody targeting CEACAM1, in patients with advanced cancer will be presented in a poster presentation at the American Society of Clinical Oncology (ASCO) 2020.
Lead Product(s): CM-24
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Kitov intends to use the net proceeds from this offering to fund the development of its oncology therapeutic candidates, and for general working capital purposes.
Lead Product(s): CM-24
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $6.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 20, 2020
Details:
Phase 1/2 study to evaluate NT-219 as Monotherapy Treatment of advanced solid tumors, as well as in combination with cetuximab to treat recurrent or metastatic Solid Tumors and Head and Neck Cancer.
Lead Product(s): NT219,Cetuximab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2020
Details:
Recognition from the USPTO validates the unique profile of Kitov’s CM-24. The mechanism of action of CM-24 results in an enhanced cytotoxic activity of the immune system cells.
Lead Product(s): CM-24
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2020
Details:
The acquisition strengthens Kitov’s oncology pipeline with the addition of novel checkpoint inhibitor, CM-24. Kitov intends to initiate a phase 1b/2a clinical trial of CM-24 + nivolumab.
Lead Product(s): CM-24,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Kitov Pharma
Deal Size: $13.5 million Upfront Cash: $13.5 million
Deal Type: Acquisition January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
